NIKKEI 225
30,526.88 -711.06 (-2.28%) HANG SENG
17,195.84 -135.38 (-0.78%) CRUDE OIL
84.75 -4.48 (-5.02%) GOLD FUTURES
1,837.70 -3.80 (-0.21%) DOW
33,129.55 +127.17 (+0.39%) Bitcoin GBP
22,768.13 +321.00 (+1.43%)
Marinus Pharmaceuticals, Inc. (0JYL.L)
| Previous close | 6.52 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 602 |
| Market cap | 3.294M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.47 |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireMarinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
RADNOR, Pa., September 21, 2023--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Cantor Global Healthcare Conference.
ZacksMarinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?
Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ZacksMarinus (MRNS) Up 20% on Financial and Pipeline Updates
Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.
